A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.
Vanderbilt University Medical Center is partnering with Evergreen Therapeutics Inc. to test whether an Alzheimer’s drug, memantine, can improve cognitive symptoms associated with systemic lupus.
Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.
Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity.
A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.
Vivian Kawai, MD, MPH, research assistant professor of Medicine, has received an LRA-BMS Accelerator Award from the Lupus Research Alliance and sponsoring partner Bristol Myers Squibb.